Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Rocci

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Blood Cancer Journal|February 15, 2020
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, et al.
Cancer Cell|October 15, 2014
Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitorsLaura Tornatore, Annamaria Sandomenico, Domenico Raimondo, et al.
Cancer Cell|September 13, 2017
Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 InhibitorsLaura Tornatore, Annamaria Sandomenico, Domenico Raimondo, et al.
Blood|February 26, 2005
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcomeMarco Ladetto, Sonia Vallet, Andreas Trojan, et al.
Leukemia & Lymphoma|September 3, 2010
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myelomaMonika Engelhardt, Josefina Udi, Martina Kleber, et al.
Plos Medicine|January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Haematologica|February 29, 2012
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disordersFiona M Ross, Hervé Avet-Loiseau, Geneviève Ameye, et al.
JAMA|July 10, 2019
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical TrialAdriana Bastidas, Javier de la Serna, Mohamed El Idrissi, et al.
Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Blood Cancer Journal|February 15, 2020
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, et al.
Cancer Cell|October 15, 2014
Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitorsLaura Tornatore, Annamaria Sandomenico, Domenico Raimondo, et al.
Cancer Cell|September 13, 2017
Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 InhibitorsLaura Tornatore, Annamaria Sandomenico, Domenico Raimondo, et al.
Blood|February 26, 2005
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcomeMarco Ladetto, Sonia Vallet, Andreas Trojan, et al.
Leukemia & Lymphoma|September 3, 2010
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myelomaMonika Engelhardt, Josefina Udi, Martina Kleber, et al.
Plos Medicine|January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Haematologica|February 29, 2012
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disordersFiona M Ross, Hervé Avet-Loiseau, Geneviève Ameye, et al.
JAMA|July 10, 2019
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical TrialAdriana Bastidas, Javier de la Serna, Mohamed El Idrissi, et al.
Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
Pageof 4